Effects of growth hormone therapy in prepubertal children with short stature secondary to intrauterine growth retardation

Chaussain, J L; Colle, M.; Landier, F

doi:10.1111/j.1651-2227.1994.tb13295.x

Cited by 35 publications

(34 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…GH was started at a mean age of 7.5 years. Five years of GH therapy at a dose of 1 vs. 2 mg/m 2 per day resulted in a significant improvement in mean (SD) height SDS of 2.12 (0.52) vs. 2.57 (0.72), respectively, and a significant increase in mean (SD) height SDS for bone age of 1.06 (0.78) vs. 1.40 (1.37), respectively [17]. After 5 years of GH therapy the mean gain in height SDS was statistically just significantly greater in children treated with the higher GH dose of 2 mg/m² per day.…”

Section: Efficacy Of Long-term Gh Treatmentmentioning

confidence: 99%

“…In a randomized, double-blind, dose-response GH trial 79 Dutch short SGA children were continuously treated until adult height with either 1 or 2 mg GH/m 2 per day [16, 17]. Children with chromosomal abnormalities, syndromes (except Silver-Russell syndrome) and severe dysmorphic symptoms were not included.…”

Section: Efficacy Of Long-term Gh Treatmentmentioning

confidence: 99%

“…Both GH dosage groups reached a mean height SDS above –2 SD within 1.3 years after the start of GH therapy. Fifty-five SGA children have reached adult height after receiving GH therapy for a mean duration of 9 years [17]. Eighty-five percent of the SGA children reached a normal adult height above 2 SDS for height, whereas 98% reached an adult height within the target height range (i.e.…”

Section: Efficacy Of Long-term Gh Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and Safety of Long-Term Continuous Growth Hormone Treatment of Children Born Small for Gestational Age

Hokken-Koelega

Pareren²,

Arends³

et al. 2004

Horm Res Paediatr

View full text Add to dashboard Cite

Twelve years of growth hormone (GH) therapy of short children born small for gestational age (SGA) have demonstrated that GH is an effective and well-tolerated therapy. Most children will reach a normal adult height (AH). AH of 55 SGA adolescents was comparable for those treated with a GH dose of 1 or 2 mg/m² (∼0.033 or 0.066 mg/kg) per day, mean (SD) AH SDS being –1.2 (0.7) and –0.8 (0.7), respectively. GH therapy had no influence on the age at onset, the progression of puberty, duration of puberty and pubertal height gain. GH therapy induced higher fasting and glucose-stimulated insulin levels after 1 and 6 years, but 6 months after GH stop, all levels returned to normal. At baseline mean systolic blood pressure was significantly increased, but both systolic and diastolic blood pressure decreased significantly during 6 years of GH and remained so after GH stop. GH therapy demonstrated a beneficial effect on serum lipid profiles, body composition, bone mineral density and head growth. Treatment with 2 mg GH/m² per day induced mean serum IGF-I levels of +2 SDS, whereas IGF-I levels remained within the normal range with 1 mg GH/m² per day. In conclusion, long-term GH therapy of short SGA children with 1 mg/m² per day appears to be effective and safe. Since the future consequences of high serum IGF-I levels during long-term GH therapy with 2 mg/m² per day are as yet unknown, it seems safer to treat short prepubertal SGA children with a GH dose of 1 mg/m² per day when children are to be treated continuously for many years.

show abstract

Section: Efficacy Of Long-term Gh Treatmentmentioning

confidence: 99%

Section: Efficacy Of Long-term Gh Treatmentmentioning

confidence: 99%

Section: Efficacy Of Long-term Gh Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Long-Term Continuous Growth Hormone Treatment of Children Born Small for Gestational Age

Hokken-Koelega

Pareren²,

Arends³

et al. 2004

Horm Res Paediatr

View full text Add to dashboard Cite

show abstract

“…Initial data were disappointing, probably due to the low dose and frequency of GH administration. Recent short term studies have shown that daily administration of recombinant human GH therapy in varying dosages accelerates growth significantly in short children born SGA (7,(15)(16)(17)(18)(19)(20)(21)(22).…”

mentioning

confidence: 99%

Growth Hormone Treatment in Children with Short Stature Born Small for Gestational Age: 5-Year Results of a Randomized, Double-Blind, Dose-Response Trial

Sas¹

1999

Journal of Clinical Endocrinology & Metabolism

137

207

View full text Add to dashboard Cite

The growth-promoting effect of continuous GH treatment was evaluated over 5 yr in 79 children with short stature (height SD score, less than Ϫ1.88) born small for gestational age (SGA; birth length SD score, less than Ϫ1.88). Patients were randomly and blindly assigned to 1 of 2 GH dosage groups (3 vs. 6 IU/m 2 body surface⅐day). GH deficiency was not an exclusion criterium. After 5 yr of GH treatment almost every child had reached a height well within the normal range for healthy Dutch children and in the range of their target height SD score. Only in children who remained prepubertal during the study period was the 5-yr increase in height SD score (HSDS) for chronological age significantly higher in the study group receiving 6 compared to 3 IU GH/m 2 ⅐day. Remarkably, the 5-yr increment in HSDS for chronological age was not related to spontaneous GH secretion, maximum GH levels after provocation, or baseline insulin-like growth factor I levels. GH treatment was associated with an acceleration of bone maturation regardless of the GH dose given. The HSDS for bone age and predicted adult height increased significantly. GH treatment was well tolerated.In conclusion, our 5-yr data show that long term continuous GH treatment at a dose of 3 or 6 IU/m 2 ⅐day in short children born SGA results in a normalization of height during childhood followed by growth along the target height percentile. (J Clin Endocrinol Metab 84: 3064 -3070, 1999)

show abstract

“…(27)(28)(29)(30)(31)(32)(33). O efeito dose-dependente nos primeiros anos de tratamento se tornou evidente (29,30,34,35). Um ganho médio na altura de 1,72 DP foi demonstrado após três anos de tratamento nas crianças recebendo 0,1 UI/kg/dia de GH, comparado com um ganho médio de 2,54 DP nas crianças recebendo 0,2 UI/kg/dia.…”

Section: Tratamento Com Hormônio De Crescimentounclassified

Tratamento com hormônio de crescimento em crianças com baixa estatura nascidas pequenas para a idade gestacional

Boguszewski¹,

Boguszewski

2008

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Aproximadamente 10% das crianças nascidas pequenas para a idade gestacional (PIG) não apresentam recuperação pós-natal do crescimento e permanecem com baixa estatura na infância e na vida adulta. Em alguns casos é possível identificar alterações no eixo GH/IGF-1. Em outros, a avaliação com os recursos diagnósticos disponíveis até o momento é normal. O tratamento com GH tem mostrado resultados promissores com recuperação do crescimento e da altura adulta dentro do esperado para a população. Nesta revisão são apresentados resultados do tratamento com GH em crianças com baixa estatura nascidas PIG ressaltando a necessidade do tratamento precoce.

show abstract

Effects of growth hormone therapy in prepubertal children with short stature secondary to intrauterine growth retardation

Cited by 35 publications

References 1 publication

Efficacy and Safety of Long-Term Continuous Growth Hormone Treatment of Children Born Small for Gestational Age

Efficacy and Safety of Long-Term Continuous Growth Hormone Treatment of Children Born Small for Gestational Age

Growth Hormone Treatment in Children with Short Stature Born Small for Gestational Age: 5-Year Results of a Randomized, Double-Blind, Dose-Response Trial

Tratamento com hormônio de crescimento em crianças com baixa estatura nascidas pequenas para a idade gestacional

Contact Info

Product

Resources

About